PEREGRINE ANNOUNCES DEFENSE DEPARTMENT GRANT TO STUDY TARVACIN PLATFORM FOR PROSTATE CANCER
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM - News), a biopharmaceutical company
with a portfolio of innovative, clinical-stage product candidates for viral
diseases and cancer, today announced the U.S. Department of Defense Prostate
Cancer Research Program has awarded a grant totaling $582,988 to the University
of Texas Southwestern Medical Center at Dallas to study the use of vascular
targeting antibodies in combination with chemotherapy agents for the treatment
of prostate cancer.